FDA Approves Subcutaneous Ocrelizumab for Multiple Sclerosis
Understanding the Benefits and Implications of the New Subcutaneous Ocrelizumab Injection for MS Patients
Topline: The FDA has approved a new subcutaneous formulation of ocrelizumab, offering a more convenient, twice-yearly treatment option for relapsing and primary progressive multiple sclerosis, with comparable efficacy and safety to the existing intravenous version.
Study Details: The approval of subcutaneous ocrelizumab (Ocrevus Zunovo) marks a significa…
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.